Enlivex Therapeutics Ltd. (TLV: ENLV)

Market Cap	121.69M
Revenue (ttm)	n/a
Net Income (ttm)	-83.94M
Shares Out	n/a
EPS (ttm)	-4.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,304
Open	482.60
Previous Close	482.60
Day's Range	480.40 - 528.50
52-Week Range	444.10 - 1,600.00
Beta	1.03
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Oren Hershkovitz
• Country: Israel
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: ENLV

Financial Performance

Financial numbers in USD